Equities analysts expect AtriCure, Inc. (NASDAQ:ATRC) to report earnings of ($0.24) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for AtriCure’s earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.25). AtriCure reported earnings of ($0.21) per share in the same quarter last year, which would indicate a negative year over year growth rate of 14.3%. The company is expected to report its next earnings results on Thursday, October 26th.
According to Zacks, analysts expect that AtriCure will report full-year earnings of ($0.97) per share for the current financial year, with EPS estimates ranging from ($0.99) to ($0.96). For the next year, analysts forecast that the company will report earnings of ($0.71) per share, with EPS estimates ranging from ($0.75) to ($0.67). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover AtriCure.
AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, July 27th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.05. AtriCure had a negative net margin of 19.56% and a negative return on equity of 19.56%. The firm had revenue of $45.23 million during the quarter, compared to analyst estimates of $44.15 million. During the same quarter last year, the business earned ($0.26) EPS. The company’s revenue was up 14.0% compared to the same quarter last year.
A number of equities analysts recently commented on ATRC shares. Stifel Nicolaus restated a “buy” rating and set a $25.00 target price on shares of AtriCure in a report on Sunday, July 30th. Zacks Investment Research downgraded AtriCure from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Leerink Swann restated an “outperform” rating and set a $26.00 target price on shares of AtriCure in a report on Friday, June 16th. BidaskClub downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $26.00 target price (up previously from $25.00) on shares of AtriCure in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $25.83.
AtriCure (NASDAQ ATRC) traded up 0.04% during mid-day trading on Friday, hitting $22.51. 91,931 shares of the stock traded hands. The company has a 50-day moving average of $21.80 and a 200 day moving average of $21.85. AtriCure has a 1-year low of $14.78 and a 1-year high of $25.18. The firm’s market capitalization is $772.86 million.
COPYRIGHT VIOLATION WARNING: “-$0.24 EPS Expected for AtriCure, Inc. (ATRC) This Quarter” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/10/10/0-24-eps-expected-for-atricure-inc-atrc-this-quarter.html.
In other AtriCure news, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total value of $224,000.00. Following the completion of the transaction, the director now owns 29,967 shares in the company, valued at $671,260.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 10.00% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATRC. Neuberger Berman Group LLC purchased a new stake in shares of AtriCure in the first quarter worth $10,849,000. Loomis Sayles & Co. L P grew its stake in shares of AtriCure by 73.5% in the first quarter. Loomis Sayles & Co. L P now owns 771,365 shares of the medical device company’s stock worth $14,772,000 after acquiring an additional 326,712 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of AtriCure by 5.6% in the first quarter. Wellington Management Group LLP now owns 3,313,575 shares of the medical device company’s stock worth $63,456,000 after acquiring an additional 176,025 shares during the last quarter. FMR LLC grew its stake in shares of AtriCure by 2.7% in the first quarter. FMR LLC now owns 4,950,000 shares of the medical device company’s stock worth $94,793,000 after acquiring an additional 130,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of AtriCure by 5.7% in the first quarter. Vanguard Group Inc. now owns 1,393,971 shares of the medical device company’s stock worth $26,695,000 after acquiring an additional 75,266 shares during the last quarter. 82.11% of the stock is currently owned by hedge funds and other institutional investors.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about AtriCure Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AtriCure Inc. and related companies.